Cordi-B (02487.HK) announced that the results of the Chinese phase III clinical trial of the Group's treatment of non-nodular moderate to severe acne vulgaris product CU-10201 (4% minocycline foam for external use) were presented in the form of an oral report at the 13th Asian Dermatology Academic Annual Conference (13th ADC Annual Meeting).
科笛-B(02487.HK)：CU-10201(外用4%米诺环素泡沫剂)中国III期临床试验结果在第十三届ADC年会发布
Cordi-B (02487.HK): CU-10201 (4% minocycline foam for external use) China Phase III clinical trial results released at the 13th ADC Annual Conference
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.